Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gatipotuzumab and Tomuzotuximab in EGFR-Positive Solid Tumors
NCT03360734Phase 1Completed
- Sponsor
- Glycotope
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Gatipotuzumab in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Glycotope. Primary endpoints: Incidence and Severity of Adverse Events and Infusion Related Reactions at 12 months and Overall Tolerability at 12 months. Started Nov 2017; status: completed.
02
Drugs
Gatipotuzumab
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)breast cancer
Beyond the preview
Go deeper on NCT03360734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360734.